[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638849":3},{"organization":4,"armGroups":7,"interventions":32,"overallOfficials":51,"centralContacts":55,"locations":65,"responsibleParty":90,"collaborators":92,"id":99,"slug":100,"hasResults":101,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":38,"eligibilityCriteria":104,"healthyVolunteers":101,"sex":105,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":38,"studyType":111,"phases":112,"briefSummary":114,"conditions":115,"keywords":38,"overallStatus":68,"whyStopped":38,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},{"fullName":5,"class":6},"The Second Affiliated Hospital of Chongqing Medical University","OTHER",[8,15,20,24,28],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","EXPERIMENTAL","Nucleotide analogs combined with anti-PD-L1 antibody (ASC22). Drug: Anti-PD-L1 antibody Once two weeks, 1mg\u002Fkg, subcutaneous injection for the first 24 weeks Drug: Nucleotide analogs Once\u002Fday, 1 capsule\u002Ftime, oral",[13,14],"Drug: Anti-PD-L1 antibody (ASC22)","Drug: Nucleotide analogs",{"label":16,"type":10,"description":17,"interventionNames":18},"Cohort 2","Anti-PD-L1 antibody\u002Fpegylated interferon alfa (Peg-IFNα) combined with nucleotide analogs Drug: Anti-PD-L1 antibody Once two weeks, 1mg\u002Fkg, subcutaneous injection for the first 24 weeks Drug: Peg-IFNα Once\u002Fweek, 180μg\u002Ftime, subcutaneous injection for the second 24 weeks Drug: nucleotide analogs Once\u002Fday, 1 capsule\u002Ftime, oral",[13,14,19],"Drug: Peg-IFNα",{"label":21,"type":10,"description":22,"interventionNames":23},"Cohort 3","Peg-IFNα\u002FAnti-PD-L1 antibody combined with nucleotide analogs Drug: Anti-PD-L1 antibody Once two weeks, 1mg\u002Fkg, subcutaneous injection for the second 24 weeks Drug: Peg-IFNα Once\u002Fweek, 180μg\u002Ftime, subcutaneous injection for the first 24 weeks Drug: nucleotide analogs Once\u002Fday, 1 capsule\u002Ftime, oral",[13,14,19],{"label":25,"type":10,"description":26,"interventionNames":27},"Cohort 4","Peg-IFNα combined with nucleotide analogs Drug: Peg-IFNα Once\u002Fweek, 180μg\u002Ftime, subcutaneous injection for 48 weeks Drug: nucleotide analogs Once\u002Fday, 1 capsule\u002Ftime, oral",[14,19],{"label":29,"type":10,"description":30,"interventionNames":31},"Cohort 5","Nucleotide analogs Drug: nucleotide analogs Once\u002Fday, 1 capsule\u002Ftime, oral",[14],[33,39,47],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"DRUG","Anti-PD-L1 antibody (ASC22)","Once two weeks, 1mg\u002Fkg, subcutaneous injection",[9,16,21],null,{"type":34,"name":40,"description":41,"armGroupLabels":42,"otherNames":43},"Nucleotide analogs","Once\u002Fday, 1 capsule\u002Ftime, oral",[9,16,21,25,29],[44,45,46],"Entecavir","Tenofovir disoproxil fumarate","Tenofovir alafenamide fumarate",{"type":34,"name":48,"description":49,"armGroupLabels":50,"otherNames":38},"Peg-IFNα","Once\u002Fweek, 180μg\u002Ftime, subcutaneous injection",[16,21,25],[52],{"name":53,"affiliation":5,"role":54},"Hong Ren, MM","STUDY_DIRECTOR",[56,61],{"name":57,"role":58,"phone":59,"phoneExt":38,"email":60},"Dachuan Cai, MD","CONTACT","+86 18323409779","cqmucdc@cqmu.edu.cn",{"name":62,"role":58,"phone":63,"phoneExt":38,"email":64},"Min Chen, PhD","+86 17338600343","mchen@hospital.cqmu.edu.cn",[66],{"facility":67,"status":68,"city":69,"state":70,"zip":71,"country":72,"countryCode":73,"cosmosGeoPoint":74,"geoPoint":79,"contacts":80},"The 2nd affiliated Hospital of Chongqing Medical University","RECRUITING","Chongqing","Chongqing Municipality","400010","China","CN",{"type":75,"coordinates":76},"Point",[77,78],106.55771,29.56026,{"lat":78,"lon":77},[81,85,88],{"name":82,"role":58,"phone":83,"phoneExt":38,"email":84},"HONG REN","+8613983888786","renhong0531@vip.sina.com",{"name":86,"role":58,"phone":87,"phoneExt":38,"email":60},"Dachuan Cai","+8618323409779",{"name":82,"role":89,"phone":38,"phoneExt":38,"email":38},"PRINCIPAL_INVESTIGATOR",{"type":91,"investigatorFullName":38,"investigatorTitle":38,"investigatorAffiliation":38,"oldNameTitle":38,"oldOrganization":38},"SPONSOR",[93,95,97],{"name":94,"class":6},"First Affiliated Hospital of Chongqing Medical University",{"name":96,"class":6},"Three Gorges Hospital of Chongqing University",{"name":98,"class":6},"Guizhou Provincial People's Hospital","100638849","phase-4-asc22-combined-with-peg-ifna-in-achieving-functional-cure-in-patients-with-chronic-hepatitis-b-virus-infection-100638849",false,"NCT07573943","ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection","Inclusion Criteria:\n\n1. Body mass index (BMI) of 18 to 32 kg\u002Fm\\^2;\n2. Serum HBsAg\\\u003C100 IU\u002FmL;\n3. HBV DNA\\\u003C20 IU\u002FmL;\n4. HBeAg-negative.\n\nExclusion Criteria:\n\n1. A history of allergy, or who are suspected by the researcher to be allergic to the active ingredient of the drug under study or its excipients;\n2. Use of immunosuppressants, immunomodulators (thymosin) and cytotoxic drugs within 6 months before enrollment, or vaccination of live attenuated vaccine within 1 month before enrollment;\n3. Acute infection within 2 weeks before enrollment which requires intravenous antibiotic treatment, or existing infection which requires anti-infection treatment when enrollment;\n4. Confirmed or suspected decompensated cirrhosis;\n5. Malignant tumors;\n6. Serious diseases of circulatory, respiratory, urinary, blood, metabolic, immune, mental, neurological, renal and other systems;\n7. Hepatitis C virus (HCV) antibody (+), HIV antigen\u002Fantibody (+), or treponema pallidum antibody (+) and rapid plasma regain (RPR) test (+);\n8. Female in suckling period or pregnancy test (+) during screening;\n9. Subjects who are considered by the researcher to have other factors that are not suitable for the study","ALL","18 Years","70 Years",{"count":109,"type":110},150,"ESTIMATED","INTERVENTIONAL",[113],"PHASE4","Exploring the safety and efficacy of the therapy combining immune checkpoint inhibitors (anti-PD-L1 monoclonal antibody, ASC22) and pegylated interferon alfa (Peg-IFNα) in patients with CHB. Exploring new combination therapeutic schemes for hepatitis B cure, and raising the overall clinical cure rate to more than 50% without screening specific advantageous groups.",[116],"Chronic Hepatitis b","2026-05-05",{"date":119,"type":120},"2026-05-07","ACTUAL",{"date":122,"type":120},"2024-05-21",{"date":124,"type":110},"2026-12-31",{"name":5,"class":6},1]